HematologyNews.net

Hematology Xagena

Search results for "Acute lymphoblastic leukemia"

Exposure to infections in the first months and years of life is known to be necessary for normal development of immune system, and children who are not exposed may be more likely than those who are t ...


In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection. ...


The results from five studies highlighting new advances in the treatment of chronic myeloid leukemia ( CML ) – a slow-progressing, malignant bone marrow cancer – have been presented at the 47th Annual ...


The FDA ( Food and Drug Administration ) has expanded the approved use of Oncaspar ( Peg-Asparaginase ) to include treating children and adults with newly diagnosed acute lymphoblastic leukemia ( ALL ...


A 5-year follow-up of patients with chronic myeloid leukemia ( CML ) who began continuous treatment with Imatinib ( Glivec / Gleevec ) reports that the drug can induce durable hematologic and cytogene ...


Researchers at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia ( ALL ) susceptible to the toxic side ef ...


Novel treatments have shown improvements in survival and response rates for leukemia and lymphoma. The use of Dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the ...


T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation ( HSCT ) is a suitable option for patients in need of an allograft who lack a HLA-matched donor. Although it offers the advan ...


In acute lymphoblastic leukemia ( ALL ) response to therapy is usually measured by microscopic analysis of the bone marrow. The detection level for leukemic cells by this method is 5%. With molecular ...


Acute lymphoblastic leukemia ( ALL ) is a rare type of blood cancer which is mainly treated by intensive chemotherapy. If the disease is resistant to initial treatment or reoccurs ( relapse ) the cha ...


The Pharmacovigilance Risk Assessment Committee ( PRAC ) of the European Medicines Agency ( EMA ) has concluded its review of Iclusig ( Ponatinib ) under the Article 20 referral procedure and has reco ...


The FDA ( Food and Drug Administration ) has granted approval of Blincyto ( Blinatumomab ) for the treatment of patients with Philadelphia chromosome-negative ( Ph- ) relapsed or refractory B-cell pre ...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias harboring these mutations may respond to ALK inhibitors such as Crizot ...


Ninety-three percent of pediatric patients ( 55 of 59 ) with relapsed/refractory acute lymphoblastic leukemia ( ALL ) went into remission after receiving an investigational therapy made from their own ...


Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto ) in adults with relapsed or refractory Philadelphia chromosome-positive ( ...